Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Investor Day (April 2025)
24 slides from Angiodynamics's investor day presentation, Apr 2, 2025
Slide 1: Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes.
INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes.
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial positi
Slide 3: AngioDynamics
AngioDynamics We are a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by focusing on cardiovascular disease and cancer. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expa
Slide 4: AngioDynamics Summary
AngioDynamics Summary AngioDynamics Summary 4
Slide 5: AngioDynamics Cardiovascular Portfolio
Venous Thromboembolism (VTE) $5.3B US TAM* AngioDynamics Cardiovascular Portfolio Differentiated technologies and a comprehensive portfolio enable us to be a strong competitor within high growth Cardiovascular Disease market Cardiovascular Disease Cancer MINI STICK MAX Prostate Care $780M US TAM* Pe
Slide 6: AngioDynamics MedTech Revenue Contribution
AngioDynamics MedTech Revenue Contribution ~15% ~45% FY2021 $3.0B FY2023 $6.0B FY2025 $10.0B FY2018 $1.3B Total Addressable Markets Our demonstrated successful execution in portfolio optimization, clinical and regulatory expansion, and product introductions drives growth… Med TechGrowth Cardiovascul
Slide 7: Venous Arterial
VENOUS ARTERIAL 7
Slide 8: Cardiovascular Arterial: Auryon Atherectomy System
Cardiovascular Arterial With over 100,000 patients treated,6 the Auryon Atherectomy System is projected in FY25 to exceed cumulative sales of $180M since its September 2020 launch 7 Served $500M M A R K E T D Y N A M I C S Auryon ~10%+ ABT 38% BSX 6% PHG 15% MDT 31% ANGO 10% Treat all levels of calc
Slide 9: Peripheral Artery Disease (PAD)
P E R I P H E R A L A R T E R Y D I S E A S E (PAD) Aspiration capability and indicated for ISR and to aspirate thrombus adjacent to stenosis Intuitive, Windows-based touch screen Small and portable (29 in x 13 in x 37 in) Lightweight (198.45 lbs.) 110 V power outlet No calibration and minimal warm
Slide 10: Auryon Platform Technology
Auryon Platform Technology The Auryon System is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium10,11,14 Wavelength (nm) The distance between 2 successive waves determines absorption rate and penetration depth Pulse wi
Slide 11: Auryon Platform Technology: Dual Method of Action
Auryon Platform Technology The Auryon System’s dual method of action: Micro-CT Study21 Intimal Plaque/Calcium Debulking Works on removing different plaque morphologies, ATK – BTK and ISR Plaque/Calcium Modification Photomechanical shockwaves penetrate the medial wall to crack/modify plaque to bring
Slide 12: Auryon Platform Technology: Expansion into Coronary Artery Disease
Patient Enrollment Beginning Q2 CY 2025 RCT: 224 Patients Registry: ~1,500 Patients Initial European Experience in Coronary Artery Disease Auryon Platform Technology The Auryon System's technology has demonstrated safety and efficacy in PAD and presents an opportunity to expand into additional disea
Slide 13: Venous Arterial: AngioVac and AlphaVac Indications
VENOUS ARTERIAL The AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours. The AlphaVac cannula is indicated for the non-surgical removal of thrombi or emboli and aspiration of contrast media
Slide 14: Cardiovascular Venous
Cardiovascular Venous Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity TAM $6B PE $3B DVT $3B Right Heart $120M Deep Vein Thrombosis (DVT) Mechanical Thrombectomy is estimated to have penetrated ~15% of the TAM 22 Mechanical Thrombectomy is expec
Slide 15: AngioVac and AlphaVac Systems
The AngioVac System allows for the continuous aspiration of embolic material such as thrombi and emboli from the venous system while simultaneously reinfusing the patient’s own filtered blood to limit procedural blood loss. MULTIPLE TIP ANGLES 200, 850, 1800 Proprietary Funnel Design Allows for Sign
Slide 16: AngioVac Technology
AngioVac Technology The only system that enables continuous aspiration and simultaneous reinfusion of blood, empowering physicians to treat more complex cases using minimally invasive techniques Aspiration & Simultaneous Reinfusion Proprietary Funnel On-circuit aspiration provides surgical results v
Slide 17: AngioVac Clot Removal Procedure Results
Actual procedure results, these images represent the experience of one institution and are not indicative of all procedural results. Clot Removal 30 min. *Dr. Keeling is a paid consultant of AngioDynamics EMORY HOSPITAL – MIDTOWNDr. Brent Keeling* (CT) 17
Slide 18: AlphaVac Technology
AlphaVac Technology Handle & Control Features MALE AND FEMALE CONNECTION Ensures correct connection SYRINGE BARREL VOLUME LIMITING SWITCH Intuitive location | Multiple glove sizes DURABLE LABELS Visible in low light environments VACUUM LOCK Controlled, single-hand design ANGLED HILT Easy access to v
Slide 19: Advanced - Large Bore Aspiration
Advanced - Large Bore Aspiration CANNULA Proprietary FUNNEL Manual Aspiration HANDLE Complete SYSTEM IU HEALTHDr. Thomas Casciani (IR) & Dr. Sabah Butty* (IR) *Dr. Butty is a paid consultant of AngioDynamics Actual procedure results, these images represent the experience of one institution and are n
Slide 20: Pulmonary Embolism Indication
Pulmonary Embolism Indication Study Approval March 2022 Enrolling October 2022 Enrollment Complete December 2023 Study Complete January 2024 CE Mark Approval May 2024 FDA Clearance AlphaVac F1885 for PE April 2024 Publication of APEX-AV Trial Results in JSCAI January 2025 20 Only the AlphaVac F1885
Slide 21: APEX-AV Pivotal Study
APEX – AV Pivotal Study 21 Number of Sites 25 US Sites Number of Patients 122 Timeline Oct. 2022 – Dec 2023 APEX (AlphaVac) FLARE (FlowTriever ) EXTRACT-PE28 (Indigo) Reduction in Clot Burden 35.5% 9.3% 11.3% AlphaVac F1885 received FDA clearance for PE following APEX-AV study demonstrating efficacy
Slide 22: AngioDynamics Summary
AngioDynamics Summary Our Med Tech segment operates in key markets with unique technologies that deliver proven clinical outcomes We have a strong track record in portfolio management, R&D, clinical and regulatory expansion, and customer-centric sales & marketing Our Med Device segment funds investm
Slide 23: Shaping the Future of Cardiovascular Care
Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes. INVESTOR EVENT
Slide 24: References
References FULL RISK INFO: https://www.angiodynamics.com/about-us/risk-information Management estimates & industry sources https://pmc.ncbi.nlm.nih.gov/articles/PMC10809869/#:~:text=Cardiovascular%20diseases%20have%20remained%20the,recorded%20in%202021%20%5B1%5D. https://pmc.ncbi.nlm.nih.gov/article